Department of Neuroscience, Azienda Ospedaliera Universitaria Integrata, Piazzale A. Stefani 1, 37126, Verona, Italy.
Emergency Department, Hospital San Bonifacio, Verona, Italy.
J Thromb Thrombolysis. 2018 Oct;46(3):292-298. doi: 10.1007/s11239-018-1700-8.
In clinical practice, direct oral anticoagulants (DOACs) are often started earlier (≤ 7 days) than in randomized clinical trials after stroke. We aimed to develop a nomogram model incorporating time of DOAC introduction ≤ 7 days of stroke onset in combination with different degrees of stroke radiological/neurological severity at the time of treatment to predict the probability of unfavorable outcome. We conducted a multicenter prospective study including 344 patients who started DOAC 1-7 days after atrial fibrillation-related stroke onset. Computed tomography scan 24-36 h after stroke onset was performed in all patients before starting DOAC. Unfavorable outcome was defined as modified Rankin Scale (mRS) score > 2 at 3 months. Based on multivariate logistic model, the nomogram was generated. We assessed the discriminative performance by using the area under the receiver operating characteristic curve (AUC-ROC) and calibration of risk prediction model by using the Hosmer-Lemeshow test. Onset-to-treatment time for DOAC (OR: 1.21, p = 0.030), NIH Stroke Scale (NIHSS) score at the time of treatment (OR: 1.00 for NIHSS = 0-5; OR: 2.67, p = 0.016 for NIHSS = 6-9; OR: 26.70, p < 0.001 for NIHSS = 10-14; OR: 57.48, p < 0.001 for NIHSS ≥ 15), size infarct (OR: 1.00 for small infarct; OR: 2.26, p = 0.023 for medium infarct; OR: 3.40, p = 0.005 for large infarct), and age ≥ 80 years (OR: 1.96, p = 0.028) remained independent predictors of unfavorable outcome to compose the nomogram. The AUC-ROC of nomogram was 0.858. Calibration was good (p = 2.889 for the Hosmer-Lemeshow test). The combination of onset-to-treatment time of DOAC with stroke radiological/neurological severity at the time of treatment and old age may predict the probability of unfavorable outcome.
在临床实践中,与随机临床试验相比,直接口服抗凝剂(DOAC)通常在中风后更早(≤7 天)开始使用。我们旨在建立一个列线图模型,将 DOAC 开始使用的时间≤中风发病后 7 天与治疗时不同程度的中风影像学/神经学严重程度结合起来,以预测不良结局的可能性。我们进行了一项多中心前瞻性研究,纳入了 344 名在房颤相关中风发病后 1-7 天开始使用 DOAC 的患者。所有患者在开始使用 DOAC 前均在中风发病后 24-36 小时进行计算机断层扫描。不良结局定义为 3 个月时改良 Rankin 量表(mRS)评分>2。基于多变量逻辑模型生成了列线图。我们使用受试者工作特征曲线下面积(AUC-ROC)评估了区分性能,并使用 Hosmer-Lemeshow 检验评估了风险预测模型的校准。DOAC 的发病至治疗时间(OR:1.21,p=0.030)、治疗时 NIH 中风量表(NIHSS)评分(OR:NIHSS=0-5 时为 1.00;NIHSS=6-9 时为 2.67,p=0.016;NIHSS=10-14 时为 26.70,p<0.001;NIHSS≥15 时为 57.48,p<0.001)、梗死灶大小(OR:小梗死灶为 1.00;OR:中等梗死灶为 2.26,p=0.023;大梗死灶为 3.40,p=0.005)和年龄≥80 岁(OR:1.96,p=0.028)是构成列线图的独立不良预后预测因子。列线图的 AUC-ROC 为 0.858。校准良好(Hosmer-Lemeshow 检验 p=2.889)。DOAC 发病至治疗时间与治疗时中风影像学/神经学严重程度和年龄较大的结合可能预测不良结局的可能性。